Skip to main content

Table 2 Response to PLD by baseline characteristics

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

   Response according RECIST after completion of PLD
No. of patients (%)
Characterstic No. pts. CR PR SD PD NE ORR p
All patients 129 2 (2) 32 (25) 24 (19) 62 (48) 9 (7) 34 (26)  
Age         
   < 63 64 0 (0) 15 (23) 11 (17) 36 (56) 2 (3) 15 (23) NS
   > = 63 64 2 (3) 17 (27) 13 (20) 25 (39) 7 (11) 19 (30)  
Age         
   < 50 17 0 (0) 3 (18) 2 (12) 11 (65) 1 (6) 3 (18) 0.382
   ≥50 112 2 (2) 29 (26) 22 (20) 51 (46) 8 (7) 31 (28)  
No. cardiac risk factors         
   1 - 2 88 2 (2) 19 (22) 17 (19) 43 (49) 7 (8) 21 (24) 0.346
   ≥3 41 0 (0) 13 (32) 7 (17) 19 (46) 2 (5) 13 (32)  
No. metastatic sites         
   1-3 99 2 (2) 28 (28) 21 (21) 42 (42) 6 (6) 30 (30) 0.065
   4-7 30 0 (0) 4 (13) 3 (10) 20 (67) 6 (9) 4 (13)  
Metastatic site         
   Visceral 92 0 (0) 22 (24) 15 (16) 49 (53) 6 (7) 22 (24) 0.321
   Nonvisceral 37 2 (5) 10 (27) 9 (24) 13 (35) 3 (8) 12 (32)  
Endocrine therapy         
   No 33 2 (6) 4 (12) 7 (21) 6 (49) 4 (8) 6 (18) 0.217
   Yes 96 0 (0) 28 (29) 17 (18) 46 (48) 5 (5) 28 (29)  
No. of prior chemos*         
   0 - 3 95 2 (2) 28 (30) 22 (23) 38 (40) 5 (5) 30 (32) 0.024
   ≥4 34 0 (0) 4 (12) 2 (6) 24 (71) 4 (12) 4 (12)  
Prior anthracycline         
   No 52 2 (4) 12 (23) 14 (27) 19 (36) 5 (10) 14 (27) .904
   Yes 77 0 (0) 20 (26) 10 (13) 43 (56) 4 (5) 20 (26)  
Prior taxane         
   No 56 2 (4) 19 (34) 10 (18) 21 (38) 4 (7) 21 (38) 0.012
   Yes 73 0 (0) 13 (18) 14 (19) 41 (56) 5 (7) 13 (18)  
  1. *adjuvant chemotherapy was counted as prior therapy line